NCT03339843 (MiMe-A) is a Phase 2 clinical trial of Abemaciclib in Esophageal Adenocarcinoma, sponsored by Jules Bordet Institute.

Who is sponsoring NCT03339843?

NCT03339843 is sponsored by Jules Bordet Institute.

What drugs are being tested in NCT03339843?

Interventions in NCT03339843: Abemaciclib.

What condition does NCT03339843 study?

NCT03339843 studies Esophageal Adenocarcinoma, Esophagus SCC, Cholangiocarcinoma, Urothelial/Bladder Cancer, Nos, Endometrial Cancer.

Is NCT03339843 still recruiting?

NCT03339843 is currently completed. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT03339843: MiMe-A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib

Completed Phase 2 Last updated 15 March 2024

What this trial tests

Phase 2 trial testing Abemaciclib in Esophageal Adenocarcinoma in 85 participants. Completed in 20 December 2023.

Timeline

19 December 2018

Primary endpoint
12 November 2021

20 December 2023

Quick facts

Lead sponsor	Jules Bordet Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	85
Start date	19 December 2018
Primary completion	12 November 2021
Estimated completion	20 December 2023
Sites	11 locations across Belgium, France

Drugs / interventions tested

Abemaciclib (abemaciclib) — full drug profile →

Conditions studied

Esophageal Adenocarcinoma — all drugs for Esophageal Adenocarcinoma →
Esophagus SCC — all drugs for Esophagus SCC →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Urothelial/Bladder Cancer, Nos — all drugs for Urothelial/Bladder Cancer, Nos →

Sponsor

Jules Bordet Institute

Who can join

18 and older, any sex, with Esophageal Adenocarcinoma or Esophagus SCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria. Based on the rate of FDG-avidity and the absence of deactivation of the Rb gene function in more than 95% of cases, we propose to define 5 tumour types of interest in a preliminary stage: 1. Platinum-refractory esophageal adenocarcinoma (ADC) 2. Platinum-refractory esophageal squamous cell carcinoma (SCC) 3. Platinum-refractory cholangiocarcinoma 4. Platinum-refractory and progressive after immunotherapy urothelial cancer 5. Platinum-refractory endometrial cancer

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
Park JJH, Siden E, Zoratti MJ, Dron L, et al · · 2019 · cited 260× · PMID 31533793 · DOI 10.1186/s13063-019-3664-1
Changing Landscape of Systemic Therapy in Biliary Tract Cancer.
Woods E, Le D, Jakka BK, Manne A. · · 2022 · cited 31× · PMID 35565266 · DOI 10.3390/cancers14092137
Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy.
Zhan L, Liu X, Zhang J, Cao Y, et al · · 2020 · cited 19× · PMID 32782525 · DOI 10.3892/ol.2020.11774
Systemic treatment options for advanced biliary tract carcinoma.
Xie C, McGrath NA, Monge Bonilla C, Fu J. · · 2020 · cited 17× · PMID 32748173 · DOI 10.1007/s00535-020-01712-9
CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges.
Arsenijevic T, Coulonval K, Raspé E, Demols A, et al · · 2023 · cited 10× · PMID 36765923 · DOI 10.3390/cancers15030968
Current challenges to underpinning the genetic basis for cholangiocarcinoma.
Cigliano A, Chen X, Calvisi DF. · · 2021 · cited 6× · PMID 33888034 · DOI 10.1080/17474124.2021.1915128
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.
Cadamuro M, Lasagni A, Lamarca A, Fouassier L, et al · · 2021 · cited 6× · PMID 33622120 · DOI 10.1080/13543784.2021.1880564

Verify or expand the search:

Other trials of Abemaciclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT06498648 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis · Phase 1, PHASE2 · recruiting
NCT07441369 — Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer · Phase 2 · enrolling by invitation

Other recruiting trials for Esophageal Adenocarcinoma

Currently open trials in the same condition.

NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
NCT07021066 — Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors · Phase 1 · recruiting

Other Jules Bordet Institute trials

Trials by the same sponsor.

NCT07455331 — Flash Radiotherapy for Skin Cancer · Phase 2 · not yet recruiting
NCT07431346 — Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy · NA · not yet recruiting
NCT06925984 — Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro- · NA · recruiting
NCT06523634 — Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy. · NA · recruiting
NCT06227338 — ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03339843 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jules Bordet Institute
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03339843.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing